Trillium Asset Management LLC Raises Stake in Humana Inc. $HUM

Trillium Asset Management LLC boosted its holdings in shares of Humana Inc. (NYSE:HUM) by 18.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,011 shares of the insurance provider’s stock after buying an additional 317 shares during the quarter. Trillium Asset Management LLC’s holdings in Humana were worth $492,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after acquiring an additional 1,143,662 shares during the period. Dodge & Cox boosted its holdings in Humana by 5.5% in the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock valued at $2,845,830,000 after purchasing an additional 557,175 shares during the last quarter. Pzena Investment Management LLC grew its position in Humana by 6.5% during the 2nd quarter. Pzena Investment Management LLC now owns 4,076,667 shares of the insurance provider’s stock worth $996,664,000 after purchasing an additional 247,744 shares during the period. Davis Selected Advisers raised its stake in shares of Humana by 3.3% during the 1st quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider’s stock valued at $616,873,000 after buying an additional 74,434 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of Humana by 1.6% in the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider’s stock valued at $327,293,000 after buying an additional 19,613 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 5.8%

Humana stock opened at $265.48 on Thursday. The stock has a market capitalization of $31.93 billion, a PE ratio of 20.37, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $315.35. The business has a 50 day simple moving average of $280.01 and a 200-day simple moving average of $258.90. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, topping the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion during the quarter, compared to analyst estimates of $31.99 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.16 EPS. On average, analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.3%. The ex-dividend date is Friday, December 26th. Humana’s payout ratio is 27.17%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Barclays dropped their target price on Humana from $315.00 to $245.00 and set an “equal weight” rating on the stock in a report on Friday, October 3rd. Morgan Stanley dropped their price objective on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 31st. Bank of America lifted their target price on shares of Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a report on Friday, October 10th. Guggenheim restated a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Finally, Sanford C. Bernstein raised their price target on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average target price of $299.22.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.